← All trials
NCT07136987
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Jan 31, 2031
- Completion date
- Jul 31, 2031
- First posted
- Aug 22, 2025
- Last posted
- Aug 22, 2025
- Enrollment
- 1104
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Open Source Pharma FoundationLead sponsor
- National Institute for Research in Tuberculosis, Chennai, IndiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.